REVIEW

Cell Research (2006)16: 169-173
© 2006 IBCB, SIBS, CAS All rights reserved 1001-0602/06 $ 30.00
www.nature.com/cr

TGF-β and cancer: Is Smad3 a repressor of hTERT gene?

He Li¹, Dakang Xu¹, Ban-Hock Toh¹, Jun-Ping Liu¹

¹Department of Immunology, Molecular Signaling Laboratory, Monash University, Melbourne, Australia

Correspondence: He Li Department of Immunology, Monash Medical School, AMREP, Commercial Road, Prahran, Victoria 3181, Australia. Tel.: 61-3-99030715; Fax: 61-3-99030018; E-mail: he.li@med.monash.edu.au

Table of Contents Download as printable (PDF) file Full Text (html)file Search Medline for articles by: He Li

Transforming growth factor β (TGF-β) carries out tumor suppressor activity in epithelial and lymphoid cells, whereas telomerase is required for most cancers. Although the molecular mechanisms by which TGF-β acts as a tumor suppressor are yet to be fully established, a link between TGFb and its tumor suppressor activity by telomerase has been suggested. Recently, we have noted a novel mode of action for TGF-β through which human telomerase reverse transcriptase (hTERT) gene is repressed in immortal and neoplastic cells, confirming that one of the mechanisms underlying TGF-β suppression of tumor growth may be through inhibiting hTERT gene transcription. Moreover, the inhibition of hTERT gene by TGF-β suggests a cis action of the TGF-β signaling molecule Smad3 on hTERT promoter directly. This article examines our current understanding and investigation of TGF-β regulation of telomerase activity, and presents a model in which Smad3 participates in regulating hTERT gene transcription by acting as a repressor directly. Engineering the interface between Smad3 and hTERT gene may lead to a new strategy to inhibit telomerase activity in cancer.

Cell Research (2006) 16:169-173. doi:10.1038/sj.cr.7310023; published online 13 February 2006

Keywords: telomerase, TERT, gene expression, Smad3, TGF-β, cancer